Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of Two Dose Regimens (60 mg/kg and 120 mg/kg) of Weekly Intravenous Alpha1 Proteinase Inhibitor (Human) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alpha 1 antitrypsin (Primary)
  • Indications Alpha 1-antitrypsin deficiency; Emphysema
  • Focus Registrational; Therapeutic Use
  • Acronyms SPARTA
  • Sponsors Grifols

Most Recent Events

  • 10 Aug 2026 According to Grifols media release, The last patient in the trial completed their final study visit last week, which signifies completion of follow-up for all 345 enrolled participants. Topline results are expected by the end of this year.
  • 10 Aug 2026 According to Grifols media release, the company announced the completion of the clinical portion of this study.
  • 28 Jul 2026 According to Grifols media release, the study will reach the last patient, last visit in August 2026, and top-line results are expected in the late fourth quarter of 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top